China, Sept. 21 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Phase II Study of Ivonescimab plus GEMOX for Neoadjuvant and Conversion Therapy in BTC'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600132968
Registration Time: 2026/09/20
Type: Interventional study
Primary Sponsor: Peking Union Medical College Hospital
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=343509
Published by HT Digital Content Services with permission from Health Daily Digest....